C linical treatment trials in intracerebral hemorrhage (ICH) often use several selection criteria to ensure patient safety and detect possible therapeutic benefits. This selection may reduce the trials' overall external validity (generalizability) in a general population of patients with ICH, which is of significance as treatment trials constitute an important basis for clinical guidelines and decision making. It is, therefore, important for clinicians to understand trials' applicability and what characterizes included and nonincluded patients. Previous eligibility estimates for ICH trials have been low, [1] [2] [3] and Fonville et al 1 reported that 17% to 32% of patients with ICH were not eligible for any of the 17 trials they studied.
However, eligibility for several large completed and ongoing ICH trials have not previously been estimated and an update on the subject is needed. We, therefore, assessed the (1) eligibility proportions for large surgical or medical clinical ICH trials and (2) overall characteristics and outcomes for eligible and noneligible patients, in a large consecutive and well-categorized ICH patient cohort.
Methods Trial Selection
previously described. 4 The study was approved by the Regional Ethical Review Board.
The Lund Stroke Register patients' eligibility status for each identified trial was determined on information from prospectively registered data, medical files, and baseline computed tomography scan, as described in the online-only Data Supplement. Survival status was obtained in 2011 from the National Census Office. Functional outcome (modified Rankin scale [mRS] ) was obtained from the Swedish Stroke Register or review of medical records. 4 Poor outcome was defined as mRS score of ≥4 at 90 days (range 50-150 days) or death <150 days after ICH, choosing the outcome closest to 90 days.
Statistics
Mann-Whitney U test and Pearson χ 2 test were used for descriptive statistics. Confidence intervals (CIs) for sample proportions were calculated with Wilson method. Kaplan-Meier plots were used for 30-and 365-day survival analysis. IBM SPSS statistics version 22.0 was used for statistical analyses and P values <0.05 were considered significant.
Results

Trial Identification and Patient Selection
Of 59 unique interventional ICH trials identified, 11 matched our selection criteria (Table) ; exclusion causes were phase 0/I trial (n=6) or phase II trial succeeded by a phase III trial (n=5), trial inactive/suspended (n=13), <300 patients with ICH (n=23), and unclear inclusion criteria (n=1). For eligibility estimation, we included 253 Lund Stroke Register patients with spontaneous ICH ( Figure II in the online-only Data Supplement). Survival status was available for all patients; functional outcome (functional status for survivors or death) was obtainable for 224 patients (89%; 139 eligible for ≥1 trial), with a median follow-up time of 94 days (interquartile range, 90-115) for patients who survived ≥150 days.
Eligibility proportions ranged from 2% to 36% between included trials, and 96 (38%) patients with ICH were ineligible for all of the included trials. Individual trial characteristics are shown in Figure and Table.
Baseline Characteristics Eligible Versus Noneligible ICH Patients
Compared with patients with ICH not eligible for any trial, patients eligible for ≥1 trial had higher admission level of consciousness (using Glasgow Coma Scale, P<0.001), less severe intraventricular hemorrhage (using modified Graeb Scale, P=0.001), and more often lobar and less often cerebellar ICH (P<0.001), see Table I in the online-only Data Supplement. No differences in age, sex, or ICH volume were observed (P>0.05).
Outcome Eligible Versus Noneligible ICH Patients
Eligible patients had 30-and 365-day case fatality rates of 18% (n=29) and 28% (n=44) (95% CI, 13%-25% and 22%-36%), whereas corresponding rates among noneligible 
Discussion
Eligibility for clinical trials on ICH differ greatly, and even in trials with the broadest inclusion criteria, a minority was estimated to be eligible. Compared with an unselected cohort, clinical trials generally include ICH patients with less severe baseline characteristics and better outcomes that should be considered when translating trial results into clinical practice and guidelines. However, many noneligible patients would likely also be ineligible for future trials because of serious prognosis with nonsurvivable hemorrhages or hematomas requiring life-saving surgery. We present novel eligibility and survival estimates for 7 trials, of which 4 are ongoing and 2 are recently completed. Eligibility proportions ranged from 2% to 36% with current surgical trials being the least inclusive, possibly because of negative results from the previous, more inclusive, surgical trials The International Surgical Trial in ICH (STICH-I) and Surgical Trial in Lobar ICH (STICH-II). 9, 10 In our cohort, 9% (95% CI, 6%-13%) of patients with ICH were potentially eligible for STICH-II, which is higher than reported in a previous study (4%) 1 but in line with another (8%). 2 Our eligibility estimate for the Recombinant Factor VIIa in Acute ICH trial (FAST; 17%; 95% CI, 13%-23%) was similar to an eligibility study on recombinant factor VIIa-therapy (13%-18%) 3 but higher than an all-inclusive population-based study (7%) 1 with somewhat different design compared with Lund Stroke Register. The latter study had a lower eligibility estimate for The Second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT-2; 7% versus 16%; 95% CI, 12%-21%) but a similar estimate for STICH-I (40% versus 35%; 95% CI, 30%-41%) compared with our study. 1 Our eligibility proportions were higher than the screening to enrollment ratios for FAST (9%) 7 and INTERACT-2 (10%) 8 but similar to screening results from STICH-II (8%), 10 Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III trial (CLEAR-III; 5%, online-only Data Supplement), and Antihypertensive Treatment of Acute Cerebral Hemorrhage trial (ATACH-II; 12%).
11
Our well-categorized consecutive hospital-based ICH patient cohort from a setting with high hospitalization and CT rates for patients with stroke 4 provides validity to our findings. Eligibility might have been overestimated because patients with missing data were included, and consent from all patients was assumed.
Conclusions
Our study highlights the importance of understanding how eligibility criteria affect patient selection in trial design and clinical implementation of trial results. 
Disclosures
Supplemental Methods
Comments on variable assessment
Eligibility criteria from the original publications were used for completed trials and eligibility criteria from the three online databases for clinical trial registration, ClinicalTrials.gov (www.clinicaltrials.gov), ISRCTN registry (www.isrctn.com), and the Stroke Trials Registry (www.strokecenter.org), were used for remaining, ongoing trials.
Due to the large number of patients assessed from Lund Stroke Register (LSR) and the many different selection criteria in the trials, we conducted the variable assessment in two steps. First potential eligibility was assessed using a basic set of variables (including time from stroke onset to diagnostic CT, age, ICH volume, and ICH location) with trial specific cut-offs. Second, the remaining trial specific variables were gathered for patients deemed potentially eligible in the first step. Hence, all patients do not have information about results for all individual variables.
If exact time between ICH onset and CT was missing we used the last time the patient was known to be well to determine eligibility with regard to the inclusion time of each trial. If time to CT was not possible to determine from medical reports the patients were regarded as noneligible (see supplemental Figure II ). Patients with missing data for any other eligibility criteria were regarded as potentially eligible for respective trial.
We assumed that consent to participate was possible to obtain for all patients. Two surgical trials (STICH-I and -II) used the clinical equipoise-concept for patient-selection, this criteria was not considered in the present analysis unless surgical removal of ICH was conducted in LSR-patients as described below. The clot stability-criteria used in three trials (MISTIE-III, CLEAR-III, and SWITCH, see below) was not considered in the present analysis due to lack of standardized acute-phase radiological follow-up in LSR patients.
Description of included trials and definitions of their eligibility criteria
References (trial-id or original article) are stated after each study-headline. Explanation of trial acronyms are provided in the main text ( Search: "intracerebral hemorrhage"
Filter: "randomized" 
